60
Participants
Start Date
August 27, 2010
Primary Completion Date
June 26, 2017
Study Completion Date
June 26, 2017
Cysteamine Bitartrate Delayed-release Capsules
"Participants who entered the trial from the RP103-03 study continued treatment with cysteamine bitartrate every 12 hours at the last dose level prescribed during their participation in that study.~Participants not entering the trial from Study RP103-03 were started on twice a day administration of cysteamine bitartrate at a total daily RP103 dose of 70% of their pre-study total daily stable Cystagon® dose."
Emory Children's Center, Atlanta
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Texas Children's Hospital/Baylor University, Houston
California Pacific Medical Center (CPMC) Research Institute, San Francisco
Stanford University Medical School, Stanford
Hospices Civils de Lyon, Lyon
Hôpital Arnaud Villeneuve - CHU Montpellier, Montpellier
Hopital Necker, Paris
Robert Debre Hospital, Paris
Radboud University Nijmegen Medical Center, Nijmegen
Lead Sponsor
Amgen
INDUSTRY